Search Within

Alexander Meyer Lesokhin

Formats
  1. Meeting Abstract (251)
  2. Journal Article (99)
  3. Research Letter (11)
  4. Review (7)
  5. Correspondence (3)
  6. Book Section (2)
  7. Editorial (2)
Groups
  1. Center for Hematologic Malignancies (375)
  2. Department of Medicine (375)
  3. Hematologic Malignancies Research (375)
  4. Hematologic Malignancies, Division of (375)
  5. Myeloma (375)
  6. Survivorship Research (221)

More Groups

People
  1. Hani Hassoun (199)
  2. Heather Landau (184)
  3. Sergio Giralt (182)
  4. David Chung (174)
  5. Neha Korde (170)
  6. Sham Mailankody (167)

More People

Years
  1. 2025 (6)
  2. 2024 (52)
  3. 2023 (77)
  4. 2022 (51)
  5. 2021 (31)
  6. 2020 (18)

More Years

Publications
  1. Blood (140)
  2. Clinical Lymphoma, Myeloma and Leukemia (57)
  3. Journal of Clinical Oncology (40)
  4. Biology of Blood and Marrow Transplantation (13)
  5. Leukemia and Lymphoma (13)
  6. Blood Advances (11)

More Publications

Publishers
  1. American Society of Hematology (151)
  2. Elsevier Inc. (78)
  3. American Society of Clinical Oncology (40)
  4. Nature Publishing Group (24)
  5. American Association for Cancer Research (14)
  6. Taylor & Francis Group (13)

More Publishers

Results (375)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplant: Interim analysis of the multicenter 2nd chance protocol
    Meeting Abstract

    Shah, G.; Bal, S.; Rodriguez, C.; Chhabra, S.; Bayer, R.; Costa, L.; Lambird, J.; Ferrer, C.; Parascondola, A.; Marcello, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Providing nutritional guidance for patients with plasma cell disorders - A missed opportunity for hematologists and oncologists?
    Meeting Abstract

    Sweeney, N.; Malik, M.; Jafri, M.; Derkach, A.; Chmielewski, C.; Adintori, P.; Mailankody, S.; Korde, N.; Tan, C.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is impacted positively by stool butyrate and healthier plant forward diets
    Meeting Abstract

    Shah, U.; Derkach, A.; Adintori, P.; Cross, J.; Maclachlan, K.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)
    Meeting Abstract

    Dholaria, B.; Bahlis, N.; Raje, N.; Costello, C.; Solh, M.; Levy, M.; Tomasson, M.; Dube, H.; Damore, M.; Lon, H. K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies
    Journal Article

    Chung, D. J.; Shah, G. L.; Devlin, S. M.; Ramanathan, L. V.; Doddi, S.; Pessin, M. S.; Hoover, E.; Marcello, L. T.; Young, J. C.; Boutemine, S. R.; more...
    Blood Cancer Discovery (2021)

    Fulltext@MSK | Save
  • MagnetisMM-1: A study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-targeted, CD3-engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma (MM)
    Meeting Abstract

    Levy, M.; Bahlis, N.; Raje, N.; Costello, C.; Dholaria, B.; Solh, M.; Tomasson, M.; Dube, H.; Damore, M.; Lon, H. K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study
    Journal Article

    Berdeja, J. G.; Madduri, D.; Usmani, S. Z.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Stewart, A. K.; Hari, P.; Htut, M.; Lesokhin, A.; more...
    Lancet (2021)

    Fulltext@MSK | Save
  • First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
    Journal Article

    Piha-Paul, S. A.; Geva, R.; Tan, T. J.; Lim, D. W. T.; Hierro, C.; Doi, T.; Rahma, O.; Lesokhin, A.; Luke, J. J.; Otero, J.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save